- Report
- May 2024
- 134 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Clinical Trials
- November 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- October 2024
- 160 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- January 2024
- 84 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- August 2022
- 30 Pages
Global
From €2614EUR$2,750USD£2,196GBP
- Report
- February 2024
- 180 Pages
Global
From €4724EUR$4,969USD£3,968GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4706EUR$4,950USD£3,953GBP
- Report
- February 2023
- 59 Pages
Global
From €3798EUR$3,995USD£3,191GBP
- Report
- May 2022
- 86 Pages
Global
From €1901EUR$2,000USD£1,597GBP
The Lupus Nephritis Drug market is a subset of the Immune Disorders Drugs market, which focuses on treatments for autoimmune diseases. Lupus Nephritis is a type of lupus that affects the kidneys, and is caused by the body's immune system attacking its own tissues. Treatment for Lupus Nephritis typically involves a combination of drugs, including corticosteroids, immunosuppressants, and biologics. These drugs are used to reduce inflammation, suppress the immune system, and prevent further damage to the kidneys.
The Lupus Nephritis Drug market is highly competitive, with a number of companies offering treatments for the condition. Some of the major players in the market include AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Pfizer, and Roche. These companies are actively researching and developing new treatments for Lupus Nephritis, as well as expanding their existing product portfolios. Show Less Read more